Completed PHASE4 INTERVENTIONAL NCT00352287

Study to Determine the Effects of Human Growth Hormone and Pioglitazone in Overweight, Prediabetic Adults

Effects of GH and Pioglitazone in Viscerally Obese Adults With IGT

Sponsor: Stanford University

Conditions Impaired Glucose Tolerance Metabolic Syndrome Obesity

Interventions Recombinant human growth hormone; pioglitazone

Updated 4 times since 2017 Last updated: Jul 12, 2006 Started: Mar 31, 2003 Completion: Apr 30, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Impaired Glucose Tolerance and Metabolic Syndrome and is currently completed. Stanford University leads this study, which shows 4 recorded versions since 2003 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jan 2017 — Jan 2021 [monthly]

Completed PHASE4

First recorded

Mar 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Stanford University

Data source: Stanford University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Palo Alto, United States